Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-12-22

FDA Approved: BUTRANS — Supplemental Application (Purdue Pharma LP)

View source ↗

Summary

FDA approved a supplemental application for BUTRANS (buprenorphine) from Purdue Pharma LP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BUTRANS (Buprenorphine)

Snippet

SUPPL AP for BUTRANS (BUPRENORPHINE)